LAVAL, QC, Oct. 1, 2012 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") today announced that its President and Chief Executive Officer Roberto Bellini will deliver a corporate presentation at BioContact Québec on Thursday, October 4th at 2:30 pm EST.
The Bellus presentation, in the Salle Grande-Allée at Château Laurier, Québec, will focus on KIACTA™, the Company's lead novel drug candidate that is currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis.
The presentation will also feature information about Bellus' development partnerships, and other product candidates in its pipeline.
The presentation will not be webcast, however the accompanying slides will appear in the `Investors' section of Bellus' website.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a development-focused healthcare company focusing on
products that provide innovative health solutions and address critical
unmet medical needs. KIACTA™, the Company's lead program, is a novel
drug candidate currently in a Phase III Confirmatory Study for the
treatment of AA amyloidosis, an orphan indication resulting in renal
dysfunction that often rapidly leads to dialysis and death. KIACTA™ is
partnered with global private equity firm Celtic Therapeutics Inc. AA
amyloidosis affects approximately 35,000 to 50,000 individuals in the
United States, Europe and Japan.
SOURCE: BELLUS HEALTH INC.
Adam Peeler
TMX Equicom
416-815-0700 ext. 225 | apeeler@tmxequicom.com